Bayer's Clinical Wins Land, but the Earnings Test Is Set for November 3
Published on 10/27/2026 at 06:42 | Editorial boerse-global.de
Bayer shares closed Wednesday at €45.65, up 3.9%, as investors digested a pair of pharmaceutical announcements that arrived from two very different stages of the drug-development pipeline. One is a regulatory green light in China. The other is an interim readout from a late-stage prostate cancer trial. Both strengthen the medical case for the company. Neither, on its own, tells shareholders anything concrete about revenue or profit.
That gap between clinical evidence and commercial results is where the real debate now sits.
What the DASL-HiCaP data actually showed
The interim results, released Saturday, come from the Phase III DASL-HiCaP study. According to Bayer, NUBEQA — whose active ingredient is darolutamide — cut the risk of metastases or death by 58% versus placebo. The median follow-up period was 3.8 years. Both arms of the trial paired the treatment with ADT and radiotherapy; the only difference was whether patients received NUBEQA or a placebo alongside that standard backbone.
The four-year metastasis-free survival rate came in at 95% for the NUBEQA arm against 88% for the comparison group. Bayer thus reported both a relative risk reduction and absolute survival rates at a fixed observation point — a more complete picture than a single headline number.
What the trial does not supply is any estimate of sales or earnings. A clinical endpoint of this kind establishes efficacy within the studied regimen. Translating that into a revenue line requires assumptions about uptake, pricing and reimbursement that the data themselves cannot settle.
Should investors sell immediately? Or is it worth buying Bayer?
A first-in-class approval in China
Separately, China's regulator approved Asundexian under the brand name Sunharbo. The indication covers adults who have suffered a non-cardioembolic ischemic stroke or a high-risk TIA, with the drug intended to lower the risk of further strokes. Bayer describes Asundexian as the world's first approved FXIa inhibitor — a genuine first-in-class milestone.
The two announcements should not be lumped together as equivalent wins. One is an interim analysis; the other is a granted marketing authorization in a specific territory for a specific patient population. They carry different evidentiary weight and different commercial timelines.
The Street is split on what it all adds up to
Analyst reaction captured the tension neatly. Richard Vosser of JPMorgan, according to media reports, took a positive view of the DASL-HiCaP interim data. The house kept Bayer at "Overweight" with a €61 price target.
Michael Leuchten of Jefferies read the same efficacy data as promising but characterized it as confirmation of what was already known rather than a fundamental shift. Jefferies stayed at "Hold" with a €46 target.
Those two numbers — €61 and €46 — frame the argument. One implies the pipeline news justifies a substantial re-rating. The other suggests the good science is already in the price. Note that both are valuation judgments, not forecasts of where the stock will trade.
Why confirmation may not be enough
The bear case here is not that the data are weak. It is that they may simply meet expectations that were already baked in. A positive result does not automatically generate a proportional share-price move if the market had already positioned for it.
Bayer at a turning point? This analysis reveals what investors need to know now.
The same logic applies to the Chinese approval. A granted authorization is a regulatory status, not a demonstrated contribution to the income statement. If operating progress lags behind the optimism the pharma headlines have generated, the clinical narrative alone may struggle to drive further gains.
For the bull case to hold, the medical momentum needs to be reinforced by hard evidence from the business itself — with the two feeding off each other rather than the science running ahead of the numbers.
November 3 is the next real checkpoint
Bayer is scheduled to publish its third-quarter 2026 results on November 3, 2026. That report will offer the first substantive reconciliation between elevated expectations and actual trading performance.
It would be a mistake to treat this week's pharma news as a near-term earnings effect waiting to be booked. The quarter will not settle the long-term investment case, but it will provide the next hard reference point. Until then, shareholders face a straightforward choice: decide how much commercial success they are willing to extrapolate from clinical wins, or wait for the ledger to speak first.
Ad
Bayer Stock: New Analysis - 27 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
